English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: Melanoma
Summer Safety: What You Should Know About Melanoma
After a cold and rainy winter, it’s refreshing to plan summertime outdoor activities or a day at the beach soaking up the sun. But it’s important to remember that too much sun exposure can be harmful.
3 Tips for Protecting Your Skin While Having Fun in the Sun
Jeffrey M. Farma, MD, FACS, of the American College of Surgeons’ Commission on Cancer offers three tips to protect yourself while enjoying time outdoors.
Wistar’s Dr. Noam Auslander Awarded $600K V Foundation Grant to Identify Connections between Gut Microbial Genes & Melanoma immunotherapy
The Wistar Institute’s Dr. Noam Auslander was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research to support the next three years of her research, which will use proteins of gut bacteria to predict immunotherapy benefit in melanoma.
Declare your independence from skin cancer: perform a skin self-exam this 4th of July
Brian Ingham was only 32 years old when a board-certified dermatologist discovered melanoma on his back during a routine visit to get a tattoo removed in late 2023. The Washington, D.C.-area military pilot said he knew he was at an increased risk as his mother was recently diagnosed with advanced melanoma that same year.
UC San Diego Health First in Region to Provide Novel Therapy for Melanoma
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
Shielding our heroes: Dermatologists deploy to provide free skin cancer checks to 425 NYC firefighters
The American Academy of Dermatology (AAD), in conjunction with the Firefighter Cancer Support Network, will host a free Skin Cancer Check event for an estimated 425 New York City firefighters on Saturday, June 1 at the New York City Firefighter Training Facility on Randall’s Island. The inaugural event kicks off the Academy’s Firefighter Skin Cancer Checks Initiative, a nationwide effort designed to provide free skin cancer checks to 10,000 firefighters by 2026.
Get Ready for ASCO 2024 Annual Meeting
ASCO, the largest event in cancer research, is approaching on May 31st. This year’s meeting promises to be particularly groundbreaking, with new findings and innovations that could revolutionize cancer treatment.
Plant virus treatment shows promise in fighting metastatic cancers in mice
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.
American Academy of Dermatology survey shows outdoor workers more at risk for skin cancer than average Americans
A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that outdoor workers — like those who work in construction, landscaping, emergency medical services, and postal delivery — are far more likely to get sunburned and tanned, putting themselves at increased risk for skin cancer, compared to the average American.
New American Academy of Dermatology survey: increasing number of Americans at risk of skin cancer despite knowing how to protect themselves
While skin cancer is one of the most preventable types of cancer, a recent survey of more than 1,000 U.S. adults found that an increasing number of Americans are reporting sunburn despite knowing how to protect themselves from the sun’s harmful rays.
Melanoma in black patients: check unexpected places
Even though melanoma is rarer in this population, Black patients are more at risk for getting diagnosed late and having worse survival outcomes. Not all skin cancers are caused by sun exposure, and not all melanomas originate in sun-exposed areas;…
Age-Related Changes in Skin May Contribute to Melanoma Metastases
Age-related changes that cause the skin to stiffen and become less elastic may also contribute to higher rates of metastatic skin cancer in older people, according to research by investigators from the Johns Hopkins Kimmel Cancer Center.
MILITARY MEMBERS MORE AT RISK FOR MELANOMA
U.S. veterans are at a higher risk of developing melanoma, one of the deadliest forms of skin cancer, likely due in part to the occupational hazards associated with active duty in countries near the equator where ultraviolet (UV) levels are higher.
New cell-based immunotherapy offered for melanoma
Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.
Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma
A first-of-its-kind cellular immunotherapy pioneered at Moffitt Cancer Center has received approval from the Food and Drug Administration and is now available for patients with advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors.
Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
The sunscreen paradox: McGill University researchers warn of ‘false sense of security’
Sunscreen is important, says Dr. Ivan Litvinov, but it is also the least effective way to protect your skin when compared to sun protective clothing and sun avoidance
MD Anderson Research Highlights: ESMO 2023 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
Scientists identify new pathway activated by interferon-gamma that leads to tumor cell death
Researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new role for a protein called extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that can trigger cells to self-destruct.
Jennifer Wargo, M.D., elected to the National Academy of Medicine
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Medicine (NAM) for her contributions to the understanding of melanoma treatment response and resistance to cancer therapies, including groundbreaking discoveries that reveal how the gut microbiome influences responses to immunotherapy.
Blood-based biomarker may redefine the future treatment for advanced melanoma
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma.
Study offers way to increase immune checkpoint inhibitor effectiveness in patients with MTAP-deleted cancers
The deletion of MTAP is primarily responsible for the decline in T cell function and lack of response to immune checkpoint inhibitors in patients whose tumor cells lack working copies of this gene.
MD Anderson Research Highlights for September 21, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights for August 16, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Immobilizing melanoma
Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study.
Equívoco sobre o melanoma: as peles escuras também correm risco
O mito de que pessoas com pele escura são imunes ao melanoma (um tipo de câncer de pele) persiste há muitos anos.
Error sobre el melanoma: los tonos oscuros también están en riesgo
Hace muchos años que persiste el mito de que las personas de piel oscura son inmunes al melanoma, un tipo de cáncer de piel.
Largest study on racial differences in men with melanoma shows men with skin of color have lowest survival rates
Melanoma, the most serious form of skin cancer, is highly treatable when detected early, but when the disease advances, it can lead to death. A new article published in the Journal of the American Academy of Dermatology reveals that men with melanoma — and particularly men with skin of color — are more likely to die than women with melanoma.
UCLA researchers uncover potential biomarkers of positive response to immunotherapy
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
Researchers discovered how melanoma changes its environment to support metastasis
A new study conducted at Tel Aviv University and the Sheba Medical Center reveals how melanoma cancer cells affect their close environment to support their needs – by forming new lymph vessels in the dermis in order to go deeper into the skin and spread through the body.
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
Los hombres deben tomarse en serio el melanoma
Independientemente de donde viva, la exposición al sol aumenta el riesgo de cáncer de piel. Esto es particularmente cierto en los hombres.
American Academy of Dermatology survey shows generation z adults are unfamiliar with sunburn and tanning risks
A recent American Academy of Dermatology survey of more than 1,000 U.S. adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths. In recognition of Skin Cancer Awareness Month this May, the AAD encourages everyone to practice safe sun to protect themselves from the sun’s harmful rays and reduce their risks of developing skin cancer.
Reviving exhausted T cells to tackle immunotherapy-resistant cancers
One of the biggest goals of immunotherapy is to reverse T cell exhaustion to boost the immune system’s ability to destroy cancerous cells. Researchers at Sanford Burnham Prebys studying melanoma have found a new way to make this happen.
Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference
Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at The University of Texas MD Anderson Cancer Center.
A puff of air could deliver your next vaccine (video)
Needles are an uncomfortable but necessary aspect of vaccination. But today, scientists report steps toward an alternative, relatively painless method that can deliver biological materials to cells by “shooting” them in with air. They will present their results at ACS Spring 2023.
Neoadjuvant Pembrolizumab Administered Before Surgery Improves Outcomes of Melanoma Patients
A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
Cancer patients who don’t respond to immunotherapy lack crucial immune cells
Cancer immunotherapy involves using activated T cells to destroy tumors, but it doesn’t work for all patients. Researchers at Washington University School of Medicine in St. Louis have discovered that a kind of dendritic cell is crucial for determining the effectiveness of immunotherapy. The discovery could lead to new ways to extend the benefits of immunotherapy to more patients.
Spot the cancer: new advances in melanoma detection
New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia.
Biomarker Predicts Resistance to Immunotherapies in Melanoma
Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
New research shows indoor tanning can increase melanoma risk
With the holidays almost upon us, your audience may be headed to their favorite salon to keep their summer tans. However, using tanning beds is putting them at risk for developing melanoma, the deadliest form of skin cancer. A new…
MD Anderson Research Highlights: SITC 2022 Special Edition
This special edition features upcoming presentations by MD Anderson researchers at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, including immunotherapy advances in human papillomavirus (HPV)-positive head and neck cancers, microbiome signatures linked with specialized immune-cell clusters, and promising early activity from novel immunotherapy drugs in advanced melanoma and colorectal cancer.
Researchers identify a subset of patients with early melanoma who face a very low risk of dying from the disease
Although melanoma is the most serious type of skin cancer, most patients have high chances of surviving the disease. There is evidence that more cases of melanoma are being overdiagnosed in patients who would never experience symptoms.
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
Reprogramming of immune cells shown to fight off melanoma
A new way of reprogramming our immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard to treat and devastating skin cancer, melanoma.
CANCER RESEARCH INSTITUTE TO HOST ANNUAL VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT ON NOVEMBER 11-12, 2022
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.